Status:
COMPLETED
Hepatitis B Challenge Dose in Adults (V232-059-10)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis B
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to describe the Seroprotection Rate (SPR) at least 2 years following completion of a primary series with a hepatitis B vaccine (Base Study V232-059, NCT00440531) and 1 mon...
Eligibility Criteria
Inclusion
- In general good health based on a medical history.
- Received 3 doses of an Hepatitis B vaccine in Base Study V232-059, NCT00440531 at least 2 years prior to enrollment in this study.
Exclusion
- Known history of previous Hepatitis B infection.
- History of vaccination with any Hepatitis B vaccine within the last 2 years.
- History of febrile illness.
- Known or suspected hypersensitivity to any component of HBVaxPro.
- Receipt of medication / vaccine that may interfere with study assessments.
- Known or suspected immune impairment.
- Pregnant women and nursing mothers.
Key Trial Info
Start Date :
November 30 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2011
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT01251276
Start Date
November 30 2010
End Date
April 12 2011
Last Update
September 13 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.